eli lilly and company zepbound - Search News

News

Eli Lilly Vows to Make Weight-Loss Pill in U.S.

CBS News on MSN · 23h

GLP-1 pill shows success for diabetes, weight loss, Eli Lilly says

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

The New York Times · 22h

What to Know About Eli Lilly’s Daily Pill for Weight Loss

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

Orange County Register · 17h

Lilly shares soar on new weight-loss pill that looks to pass Ozempic

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

4hon MSN

Eli Lilly and Company (LLY): One of the Best Long Term Stocks to Buy According to Billionaires

We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...

24/7 Wall St.2h

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (April 2025)

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

10hon MSN

Where Will Eli Lilly Be in 5 Years?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

1d

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results